Latest TYSABRI Stories
Data also showed reduced fatigue and improved cognition.
WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of secondary progressive multiple sclerosis, Biogen Idec/Elan's Tysabri will remain Decision Resources' proprietary clinical gold standard through 2018.
Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRIÂ® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.
Results further support the benefits of TYSABRI for multiple sclerosis patients.
INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
On Monday, Biogen Idec Inc said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year.
PatientsLikeMe, the leading online community for patients with life-changing conditions, announces the release of its newest PatientsLikeMeListen(TM) report: "Did the July 2008 PML announcement affect the Tysabri brand?" Among its findings, the report reveals that patients retained an overall positive perception of the Tysabri brand despite the July 2008 announcement of two additional PML cases.
Biogen Idec Inc. says a U.S. woman contracted a deadly brain infection while taking the drug Tysabri.
- A volcanic mudflow.